NEW YORK, September 8, 2025 — Biotia has introduced an innovative “test to treat” pathway for patients suffering from recurrent urinary tract infections (UTIs). This approach allows individuals to collect a urine sample at home, undergo advanced molecular testing via the BIOTIA-ID Urine Test, and receive virtual care from clinicians trained specifically in recurrent UTI treatment—all from the privacy of their home.
Science Significance
The BIOTIA-ID Urine Test utilizes next-generation sequencing and artificial intelligence to detect over 40 key uropathogens and generate insights into antimicrobial resistance. This method addresses the limitations of traditional urine cultures, which fail approximately 30% of the time and are particularly poor at identifying infections caused by anaerobes, fungi, and fastidious pathogens. By providing a more accurate diagnosis, the test enables clinicians to offer tailored treatment plans, improving patient
Regulatory Significance
The BIOTIA-ID Urine Test is currently available for research use only and is backed by rigorous analytical and clinical validation. While it is not yet FDA-approved for clinical diagnostics, its development aligns with ongoing efforts to enhance diagnostic accuracy and antimicrobial stewardship in the management of UTIs.
Business Significance
Advertisement
This initiative represents a strategic advancement in the field of infectious disease diagnostics. By integrating advanced molecular testing with telehealth consultations, Biotia is positioning itself at the forefront of personalized medicine. The “test to treat” model not only improves patient care but also offers a scalable solution that can be expanded to other infectious diseases in the future.
Patients’ Significance
For patients, especially those experiencing recurrent UTIs, this new pathway offers a streamlined and more accurate approach to diagnosis and treatment. The convenience of at-home sample collection, combined with virtual consultations, reduces the need for multiple in-person visits, saving time and potentially lowering healthcare costs. Moreover, the precision of the BIOTIA-ID Urine Test ensures that patients receive the most effective treatment tailored to their specific infection profile.
Policy Significance
The introduction of this advanced diagnostic and treatment model supports broader public health goals, including the reduction of antibiotic misuse and the promotion of antimicrobial stewardship. By providing clinicians with more accurate diagnostic tools, this initiative contributes to efforts aimed at combating antibiotic resistance and improving the overall quality of care in the management of UTIs.
Biotia’s launch of the “test to treat” pathway for recurrent UTIs marks a significant step forward in the integration of advanced diagnostics and personalized care. By combining cutting-edge molecular testing with telehealth consultations, this initiative not only enhances patient outcomes but also sets a new standard for the management of recurrent infections.
Source: Biotia, Inc. Press Release
